Navigation Links
Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
Date:6/22/2013

inties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

CONTACT:

Catherine London
Associate Director, Communications and Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com 
Phone: (317) 651-9116

References

  1. Ramachandran A, et al. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012; 3(6): 110–117.
  2. Asian American Diabetes Initiative. Joslin Diabetes Center, Boston, MA. http://aadi.joslin.org/content/diabetes-asians-asian-americans. Accessed on: April 9, 2013.
  3. Chen Y, et al. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a 24-week, randomized, Phase III clinical trial: Poster No. 1159-P. Presented at the American Diabetes Association 73rd Scientific Sessions®. June 21-25, Chicago, IL.
  4. Wang W, et al. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin: a 24-week, randomized, Phase III clinical trial: Poster No. 1177-P. Presented at the American Diabetes Association 73rd Scientific Sessions®. June 21-25, Chicago, IL
  5. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States<
    '/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... , May 28, 2015  Pharmaceutical ... new drugs and tests, and this is ... instruments that can assist them. This according to ... Information said instruments such as mass spectrometry, ... in the identification of drug targets and ...
(Date:5/28/2015)... May 28, 2015 Henry Schein ... provider of health care products and services to ... reminded its customers that the Henry Schein Disaster ... veterinarians who experience operational, logistical or financial issues ... the South Central region of the U.S. The ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3
... U.S. Food and Drug Administration (FDA) has accepted for ... of Keppra XR(TM) (levetiracetam) in the, adjunctive ... ATLANTA, Jan. 16 UCB announced today that ... XR(TM) (levetiracetam) extended-,release tablets in the adjunctive treatment of ...
... rate from,cancer now is lower in older adolescents and ... because of a lack of access to clinical trials,nationally ... by pediatric,oncologists at Children,s Hospital of Pittsburgh of UPMC., ... with cancer have,improved dramatically over the last 30 years, ...
Cached Medicine Technology:Keppra XR(TM) Extended-Release Tablets Filed with the FDA 2Keppra XR(TM) Extended-Release Tablets Filed with the FDA 3Keppra XR(TM) Extended-Release Tablets Filed with the FDA 4Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3
(Date:5/30/2015)... You've probably heard that using cotton swabs to clean the ... found a better way to remove ear wax? Luckily, a ... need. , They developed SUNDENG EAR CLEANER to ease the ... from the ears. What's more, it is safer and more ... today for children and adults of all ages. As such, ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 ProIntro Magnify contains 30 ... and animations. Instantly add an elegant opening title to any ... a range of clean design layouts. ProIntro Magnify is created ... is extremely easy to use. Simply drag a preset into ... on-screen-controls and parameters in the Inspector window then watch as ...
(Date:5/30/2015)... 30, 2015 At 73 years old, ... health , which she attributes to a lifetime of ... good nutrition with the release of her new book titled ... AU). , “Cook for Health and Longevity” features a collection ... mostly organic food . It is designed to encourage ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 ... today that she is offering a free analysis and ... The offer coincides with Disability Awareness Month, which was ... Industry members across the United States such as Polk ... to raise awareness about the possibility of disability, as ...
Breaking Medicine News(10 mins):Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... University of North Carolina (UNC) researchers report in the ... that narcotics and diagnostic testing are overused in treating ... more effective treatments for neck pain, such as therapeutic ... to support the effectiveness of therapeutic exercise in treating ...
... not considered effective treatment for KRAS (a gene)-mutated metastatic ... cancer not responding to chemotherapy and a certain variation ... longer overall and progression-free survival than patients with other ... issue of JAMA . "Recent retrospective ...
... 26 (HealthDay News) -- Older adults who survive severe sepsis ... with mental functioning, a new study indicates. This largely ... an increased burden on caregivers and families, as well as ... the researchers said. Also called "blood poisoning," sepsis is ...
... of Medicine and The Children,s Hospital have taken a big ... liver diseases in infants. The disease is called biliary ... which bile, crucial for digestion, flows to the small intestine. ... in 10,000 births. But it,s life-threatening. "It is ...
... , TUESDAY, Oct. 26 (HealthDay News) -- A new bivalent ... 1 and 3 -- triggers a stronger immune response than the ... vaccines, a new study shows. Use of trivalent and monovalent ... from more than 125 in 1988 to just four today. ...
... TUESDAY, Oct. 26 (HealthDay News) -- Dr. Alexander Heazell and his ... child in 2001. They planned to name him Jack. But ... pressure had shot up during the pregnancy, and at 26 weeks, ... baby was devastating for Heazell and his wife. The stress and ...
Cached Medicine News:Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Brain Deficits Higher in Seniors Who Survive Blood Poisoning 2Health News:Breakthrough in understanding life-threatening childhood liver disease 2Health News:New Polio Vaccine Shows Major Advantages: Study 2Health News:Stillbirth Can Be Devastating, Unpredictable 2Health News:Stillbirth Can Be Devastating, Unpredictable 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: